Distinctive properties of metastasis-initiating cells

Genes and Development

Volumn 30, Issue 8, 2016, Pages 892-908

  Celià Terrassa, Toni ^a   Kang, Yibin ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

Cancer metastasis; Epithelial mesenchymal transition; Metastasis initiating cells; Metastatic niche; Plasticity

Indexed keywords

APOPTOSIS; CANCER CELL; CELL FATE; CELL METABOLISM; CELL PLASTICITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE EVASION; METASTASIS; METASTASIS INITIATING CELL; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STROMA CELL; ANIMAL; ANOIKIS; CANCER STEM CELL; DRUG RESISTANCE; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANOIKIS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84963819737     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.277681.116     Document Type: Review

References (189)

1. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al. 2014. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158: 1110-1122.
2. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, et al. 2012. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150: 165-178.
3. Aguilar E, Marin de Mas I, Zodda E, Marin S, Morrish F, Selivanov V,Meca-Cortés O, Delowar H, Pons M, Izquierdo I, et al. 2016. Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program. Stem Cells doi: 10.1002/ stem.2286.
4. Barcellos-Hoff MH, Lyden D, Wang TC. 2013. The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 13: 511-518.
5. Beck B, Lapouge G, Rorive S, Drogat B, Desaedelaere K, Delafaille S,Dubois C, Salmon I, Willekens K, Marine JC, et al. 2015. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 16: 67-79.
6. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. 2008. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
7. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M,Delatte B, Caauwe A, Lenglez S, Nkusi E, et al. 2014. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511: 246-250.
8. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, KinzlerKW, Vogelstein B,Nowak MA. 2010. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci 107: 18545-18550.
9. Brabletz T. 2012. To differentiate or not-routes towards metastasis. Nat Rev Cancer 12: 425-436.
10. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K. 2000. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18: 80-86.
11. Brooks MD, Burness ML, Wicha MS. 2015. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 17: 260-271.
12. Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O'Connell M, Jernigan D, Fatatis A, et al. 2013. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest 123: 2907-2920.
13. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, et al. 2012. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22: 571-584.
14. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, Chambers AF, MacDonald IC. 2000. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 60: 2541-2546.
15. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, et al. 2010. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113.
16. Cao PD, Cheung WK, Nguyen DX. 2011. Cell lineage specification in tumor progression and metastasis. Discov Med 12: 329-340.
17. Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J,Eckhardt BL, Anderson RL. 2014. BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res 74: 5091-5102.
18. Castano Z, Marsh T, Tadipatri R, Kuznetsov HS, Al-Shahrour F, Paktinat M, Greene-Colozzi A, Nilsson B, Richardson AL, McAllister SS. 2013. Stromal EGF and IGF-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov 3: 922-935.
19. Celia-Terrassa T, Meca-Cortes O, Mateo F, de Paz AM, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M, et al. 2012. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 122: 1849-1868.
20. Chaffer CL, Thompson EW,Williams ED. 2007. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185: 7-19.
21. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukacisin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, et al. 2012. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol 14: 1212-1222.
22. Chambers AF, Groom AC, MacDonald IC. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
23. Chapman A, Fernandez del Ama L, Ferguson J, Kamarashev J, Wellbrock C, Hurlstone A. 2014. Heterogeneous tumor subpopulations cooperate to drive invasion. Cell Rep 8: 688-695.
24. Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, et al. 2012. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 31: 2461-2470.
25. Chen EI, Hewel J, Krueger JS, Tiraby C,Weber MR, Kralli A, Becker K,Yates JR III, Felding-Habermann B. 2007. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 67: 1472-1486.
26. Chen Q, Zhang XH, Massague J. 2011. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20: 538-549.
27. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, LinW, et al. 2014. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5: 5241.
28. Cheung WK, Zhao M, Liu Z, Stevens LE, Cao PD, Fang JE, Westbrook TF, Nguyen DX. 2013. Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. Cancer Cell 23: 725-738.
29. Chui MH. 2013. Insights into cancer metastasis from a clinicopathologic perspective: epithelial-mesenchymal transition is not a necessary step. Int J Cancer 132: 1487-1495.
30. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. 2014. Tumour cell heterogeneity maintained by cooperating subclones in Wntdriven mammary cancers. Nature 508: 113-117.
31. Cohen-Solal JF, Cassard L, Fournier EM, Loncar SM, Fridman WH, Sautes-Fridman C. 2010. Metastatic melanomas express inhibitory low affinity Fcγ receptor and escape humoral immunity. Dermatol Res Pract 2010: 657406.
32. Cole MD. 1986. The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 20: 361-384.
33. Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, WelmAL. 2014. TheRONreceptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep 6: 141-154.
34. Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
35. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
36. Dey S, Sayers CM, Verginadis II, Lehman SL, Cheng Y, Cerniglia GJ, Tuttle SW, Feldman MD, Zhang PJ, Fuchs SY, et al. 2015. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J Clin Invest 125: 2592-2608.
37. Dong C, Yuan T, Wu Y, Wang Y, FanTW, Miriyala S, Lin Y, Yao J, Shi J, Kang T, et al. 2013. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23: 316-331.
38. Douma S, Van LaarT, Zevenhoven J, Meuwissen R, Van Garderen E,Peeper DS. 2004. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034-1039.
39. Dupuy F, Tabaries S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, et al. 2015. PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab 22: 577-589.
40. Ell B, Kang Y. 2012. SnapShot: bone metastasis. Cell 151: 690-691.e1.
41. Fidler IJ. 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
42. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al. 2015. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527: 472-476.
43. Fofaria NM, Srivastava SK. 2015. STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis 36: 142-150.
44. Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O'Connor ST, Li S, Chin AR, et al. 2015. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17: 183-194.
45. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. 2008. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195-198.
46. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG. 2012. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150: 764-779.
47. Ghajar CM. 2015. Metastasis prevention by targeting the dormant niche. Nat Rev Cancer 15: 238-247.
48. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, et al. 2013. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15: 807-817.
49. Giancotti FG. 2013. Mechanisms governing metastatic dormancy and reactivation. Cell 155: 750-764.
50. Gilbert LA, Hemann MT. 2010. DNA damage-mediated induction of a chemoresistant niche. Cell 143: 355-366.
51. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
52. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. 2007. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
53. Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481: 306-313.
54. Gu L, Frommel SC, Oakes CC, Simon R, Grupp K, Gerig CY, Bar D,Robinson MD, Baer C,Weiss M, et al. 2015. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nat Genet 47: 22-30.
55. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Hognas G, Annala M,et al. 2015. The evolutionary history of lethal metastatic prostate cancer. Nature 520: 353-357.
56. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-Hardi U, Bell G, et al. 2012. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148: 1015-1028.
57. GuptaGP, Massague J. 2006. Cancer metastasis: building a framework. Cell 127: 679-695.
58. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R, Massague J. 2007. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci 104: 19506-19511.
59. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C,Lander ES. 2011. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146: 633-644.
60. Habu N, Imanishi Y, Kameyama K, Shimoda M, Tokumaru Y, Sakamoto K, Fujii R, Shigetomi S, Otsuka K, Sato Y, et al. 2015. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma. BMC Cancer 15: 730.
61. Hanahan D, Coussens LM. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309-322.
62. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
63. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. 2007. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7: 246-255.
64. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. 2013. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13: 714-726.
65. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T. 2010. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24: 501-505.
66. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S,et al. 2015. Tumour exosome integrins determine organotropic metastasis. Nature 527: 329-335.
67. Huang Z, Wu T, Liu AY, Ouyang G. 2015. Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget 6: 39550-39563.
68. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E,Forni G, Eils R, Fehm T, Riethmuller G, et al. 2008. Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68.
69. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A,Imanishi H, Nakada K, Honma Y, Hayashi J. 2008. ROSgenerating mitochondrialDNAmutations can regulate tumor cell metastasis. Science 320: 661-664.
70. Jacob LS, Vanharanta S, ObenaufAC, Pirun M, Viale A, Socci ND, Massague J. 2015. Metastatic competence can emerge with selection of preexisting oncogenic alleles without a need of new mutations. Cancer Res 75: 3713-3719.
71. Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN, Levine H. 2015a. Implications of the hybrid epithelial/ mesenchymal phenotype in metastasis. Front Oncol 5: 155.
72. Jolly MK, Jia D, Boareto M, Mani SA, Pienta KJ, Ben-Jacob E, Levine H. 2015b. Coupling the modules of EMT and stemness: a tunable 'stemness window' model. Oncotarget 6: 25161-25174.
73. Joyce JA, Pollard JW. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
74. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
75. Kang Y, Pantel K. 2013. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23: 573-581.
76. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C,MacDonald DD, Jin DK, Shido K, Kerns SA, et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
77. Kareta MS, Gorges LL, Hafeez S, Benayoun BA, Marro S, Zmoos AF, Cecchini MJ, Spacek D, Batista LF, O'Brien M, et al. 2015. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell 16: 39-50.
78. Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger BZ, Furth EE, Sepulveda AR, Yuan CX, Won KJ, et al. 2013. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep 3: 2088-2099.
79. Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK. 2015. Emerging strategies for treating brain metastases from breast cancer. Cancer Cell 27: 163-175.
80. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T,Mercatali L, Khan Z, Goodarzi H, Hua Y, et al. 2011. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17: 1101-1108.
81. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M,Ewald AJ, Pai SY, Ho IC, Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152.
82. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. 2009. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15: 195-206.
83. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, et al. 2015. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526: 131-135.
84. LeBleu VS,O'Connell JT, Gonzalez Herrera KN,Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, et al. 2014. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 16: 992-1003, 1001-1015.
85. Ledford H. 2011. Cancer theory faces doubts. Nature 472: 273.
86. Leng Z, Tao K, Xia Q, Tan J, Yue Z, Chen J, Xi H, Li J, Zheng H. 2013. Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PLoS One 8: e56082.
87. LiW, Kang Y. 2016. Probing the fifty shades ofEMTin metastasis. Trends Cancer 2: 65-67.
88. Li CM, Gocheva V, Oudin MJ, Bhutkar A, Wang SY, Date SR, Ng SR, Whittaker CA, Bronson RT, Snyder EL, et al. 2015. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev 29: 1850-1862.
89. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU,Walker CL, et al. 2007. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9: 218-224.
90. Liu X, Sun H, Qi J,Wang L, He S, Liu J, Feng C, Chen C, LiW, Guo Y,et al. 2013. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol 15: 829-838.
91. Liu S, Cong Y,Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, et al. 2014. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2: 78-91.
92. Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, Saltz L,Paty PB, Tavazoie SF. 2015. Extracellular metabolic energetics can promote cancer progression. Cell 160: 393-406.
93. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, et al. 2011. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 20: 701-714.
94. Lu X, Mazur SJ, Lin T, Appella E, Xu Y. 2014. The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene 33: 2655-2664.
95. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. 1998. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153: 865-873.
96. Maddipati R, Stanger BZ. 2015. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov 5: 1086-1097.
97. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J. 2012. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481: 85-89.
98. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
99. Martorana AM, Zheng G, Crowe TC, O'Grady RL, Lyons JG. 1998. Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. Cancer Res 58: 4970-4979.
100. Marusyk A, Almendro V, Polyak K. 2012. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12: 323-334.
101. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. 2014. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514: 54-58.
102. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C,et al. 2014. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159: 1603-1614.
103. Massard C, Loriot Y, Fizazi K. 2011. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol 8: 701-710.
104. Mateo F, Meca-Cortes O, Celia-Terrassa T, Fernandez Y, Abasolo I, Sanchez-Cid L, Bermudo R, Sagasta A, Rodriguez-Carunchio L,Pons M, et al. 2014. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Mol Cancer 13: 237.
105. McAllister SS,Weinberg RA. 2014. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 16: 717-72.
106. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, Cibulskis K, Bhutkar A, McKenna A, Dooley A, Vernon A, et al. 2014. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156: 1298-1311.
107. Medema JP. 2013. Cancer stem cells: the challenges ahead. Nat Cell Biol 15: 338-344.
108. Merlo LM, Pepper JW, Reid BJ, Maley CC. 2006. Cancer as an evolutionary and ecological process. Nat Rev Cancer 6: 924-935.
109. Miller FR. 1983. Tumor subpopulation interactions in metastasis. Invasion Metastasis 3: 234-242.
110. Morales M, Arenas EJ, Urosevic J, Guiu M, Fernandez E, Planet E, Fenwick RB, Fernandez-Ruiz S, Salvatella X, Reverter D, et al. 2014. RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. EMBO Mol Med 6: 865-881.
111. Moreno E. 2008. Is cell competition relevant to cancer? Nat Rev Cancer 8: 141-147.
112. Naumov GN, Townson JL, MacDonald IC,Wilson SM, Bramwell VH, Groom AC, Chambers AF. 2003. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 82: 199-206.
113. Neelakantan D, Drasin DJ, Ford HL. 2015. Intratumoral heterogeneity: clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adh Migr 9: 265-276.
114. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R,Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al. 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17: 1498-1503.
115. Nieto MA. 2013. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342: 1234850.
116. Nishikawa M. 2008. Reactive oxygen species in tumor metastasis. Cancer Lett 266: 53-59.
117. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. 2012. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22: 709-724.
118. O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, et al. 2011. VEGF-A and tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci 108: 16002-16007.
119. Okada T, Sinha S, Esposito I, Schiavon G, Lopez-Lago MA, SuW, PratilasCA, Abele C, Hernandez JM, Ohara M, et al. 2015. The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nat Cell Biol 17: 81-94.
120. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J. 2011. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 17: 867-874.
121. Oskarsson T, Batlle E, Massague J. 2014. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14: 306-321.
122. Pani G, Galeotti T, Chiarugi P. 2010. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 29: 351-378.
123. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, et al. 2012. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18: 883-891.
124. Pencheva N, Tavazoie SF. 2013. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 15: 546-554.
125. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ, Morrison SJ. 2015. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527: 186-191.
126. Polyak K, Haviv I, Campbell IG. 2009. Co-evolution of tumor cells and their microenvironment. Trends Genet 25: 30-38.
127. Porporato PE, Payen VL, Perez-Escuredo J, De Saedeleer CJ, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T, Bouzin C, et al. 2014. A mitochondrial switch promotes tumor metastasis. Cell Rep 8: 754-766.
128. Qian BZ, Pollard JW. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
129. Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423-1437.
130. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, BuchlerMW, Zoller M, et al. 2010. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70: 5004-5013.
131. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
132. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. 2012. EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361.
133. Robertson CL, Srivastava J, Siddiq A, Gredler R, Emdad L, Rajasekaran D,Akiel M, Shen XN, Guo C, Giashuddin S, et al. 2014. Genetic deletion of AEG-1 prevents hepatocarcinogenesis. Cancer Res 74: 6184-6193.
134. Rodriguez-Torres M, Allan AL. 2016. Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors. Clin Exp Metastasis 33: 97-113.
135. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. 2009. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109-113.
136. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. 1994. Disruption of the mouse mdr1a Pglycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502.
137. Schmidt JM, Panzilius E, Bartsch HS, Irmler M, Beckers J, Kari V, Linnemann JR, Dragoi D, Hirschi B, Kloos UJ, et al. 2015. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep 10: 131-139.
138. Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor RE, Hendrix MJ. 2006. The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10: 174-196.
139. Sethi N, Dai X, Winter CG, Kang Y. 2011. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19: 192-205.
140. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, et al. 2009. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813.
141. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. 2011. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121: 1298-1312.
142. Sosa MS, Bragado P, Aguirre-Ghiso JA. 2014. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14: 611-622.
143. Sosa MS, Parikh F, Maia AG, EstradaY, Bosch A, Bragado P, Ekpin E, George A, Zheng Y, Lam HM, et al. 2015. NR2F1 controls tumour cell dormancy via SOX9-and RARβ-driven quiescence programmes. Nat Commun 6: 6170.
144. Spek CA, Arruda VR. 2012. The protein C pathway in cancer metastasis. Thromb Res 129: S80-S84.
145. Stankic M, Pavlovic S, Chin Y, Brogi E, Padua D, Norton L, Massague J, Benezra R. 2013. TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-toepithelial transition. Cell Rep 5: 1228-1242.
146. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel WT, et al. 2008. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13: 441-453.
147. Su Z, Yang Z, Xu Y, Chen Y, Yu Q. 2015. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer 14: 48.
148. SunY, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. 2012. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18: 1359-1368.
149. Tabassum DP, Polyak K. 2015. Tumorigenesis: it takes a village. Nat Rev Cancer 15: 473-483.
150. Talmadge JE,Wolman SR, Fidler IJ. 1982. Evidence for the clonal origin of spontaneous metastases. Science 217: 361-363.
151. Tam WL,Weinberg RA. 2013. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19: 1438-1449.
152. Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, et al. 2013. Protein kinase Cα is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24: 347-364.
153. Tang YN, Ding WQ, Guo XJ, YuanXW,Wang DM, Song JG. 2015. Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat Commun 6: 8230.
154. Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
155. Thomas DA, Massague J. 2005. TGF-β directly targets cytotoxicT cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380.
156. Tran DD, CorsaCA, Biswas H, Aft RL, Longmore GD. 2011. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res 9: 1644-1657.
157. Tran HD, Luitel K, Kim M, Zhang K, Longmore GD, Tran DD. 2014. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res 74: 6330-6340.
158. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. 2012. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22: 725-736.
159. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF. 2008. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 68: 10377-10386.
160. Unternaehrer JJ, Zhao R, Kim K, Cesana M, Powers JT, Ratanasirintrawoot S, Onder T, Shibue T, Weinberg RA, Daley GQ. 2014. The epithelial-mesenchymal transition factor SNAIL paradoxically enhances reprogramming. Stem Cell Rep 3: 691-698.
161. Vaira V, Faversani A, Martin NM, Garlick DS, Ferrero S, Nosotti M,Kissil JL, Bosari S, Altieri DC. 2013. Regulation of lung cancer metastasis by Klf4-Numb-like signaling. Cancer Res 73: 2695-2705.
162. Valastyan S, Weinberg RA. 2011. Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-292.
163. Valiente M, ObenaufAC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, et al. 2014. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156: 1002-1016.
164. Vanharanta S, Massague J. 2013. Origins of metastatic traits. Cancer Cell 24: 410-421.
165. Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, Kushida M, Head R, Morrissy S, Zhu X, et al. 2014. Quiescent sox2+ cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell 26: 33-47.
166. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546-1558.
167. Wagenblast E, Soto M, Gutierrez-Angel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, et al. 2015. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520: 358-362.
168. Wan L, Pantel K, Kang Y. 2013. Tumor metastasis: moving new biological insights into the clinic. Nat Med 19: 1450-1464.
169. Wan L, Hu G, Wei Y, Yuan M, Bronson RT, Yang Q, Siddiqui J, Pienta KJ, Kang Y. 2014a. Genetic ablation of metadherin inhibits autochthonous prostate cancer progression and metastasis. Cancer Res 74: 5336-5347.
170. Wan L, Lu X, Yuan S, WeiY, Guo F, Shen M, Yuan M, Chakrabarti R,Hua Y, Smith HA, et al. 2014b. MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene-and carcinogen-induced mammary tumors. Cancer Cell 26: 92-105.
171. Wang QE. 2015. DNAdamage responses in cancer stem cells: implications for cancer therapeutic strategies. World J Biol Chem 6: 57-64.
172. Wang D, Cai C, Dong X, Yu QC, Zhang XO, Yang L, Zeng YA. 2015a. Identification of multipotent mammary stem cells by protein C receptor expression. Nature 517: 81-84.
173. Wang H, Yu C, Gao X, Welte T, Muscarella AM, Tian L, Zhao H, Zhao Z, Du S, Tao J, et al. 2015b. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27: 193-210.
174. Weber GF. 2016. Metabolism in cancer metastasis. Int J Cancer 138: 2061-2066.
175. Weilbaecher KN, Guise TA, McCauley LK. 2011. Cancer to bone: a fatal attraction. Nat Rev Cancer 11: 411-425.
176. Westcott JM, Prechtl AM, Maine EA, Dang TT, Esparza MA, Sun H,Zhou Y, Xie Y, Pearson GW. 2015. An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. J Clin Invest 125: 1927-1943.
177. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, et al. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473: 101-104.
178. Wu WS. 2006. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 25: 695-705.
179. Xing F, Kobayashi A, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S,Wilber A, Mo YY, Moore BE, et al. 2013. Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. EMBO Mol Med 5: 384-396.
180. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al. 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
181. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA. 2015. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525: 256-260.
182. Yu M, Bardia A,Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al. 2013. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 580-584.
183. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J. 2009. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16: 67-78.
184. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al. 2012. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-860.
185. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, et al. 2015. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527: 100-104.
186. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. 2015a. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527: 525-530.
187. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. 2015b. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527: 525-530.
188. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al. 2001. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034.
189. ZhouW, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, et al. 2014. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25: 501-515.